JPMorgan Ultra Short Income ETF vs Moderna, Inc. — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.46, while Moderna, Inc. trades at $62.21 (market cap $24.18B). The key difference: Moderna, Inc. is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| JPST | MRNA | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $50.78 | $81.80 |
52-Week Low | $50.40 | $22.36 |
Market Cap | — | $24.18B |
Enterprise Value | — | $20.33B |
Signals from Pluang's Aura AI — not financial advice
JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.465, up 0.05% with a bearish technical signal. The ETF focuses on high-quality, short-term bonds, offering a cash alternative with consistent dividends. Recent institutional buying includes Financial Management Professionals increasing its stake by 4.7% in Q2 2026 (SEC filing, August 11, 2026).
Outlook remains stable for risk-averse investors seeking yield with low volatility. Key risks include interest rate hikes and inflation pressures, as noted in Fed commentary (Zacks Investment Research, July 31, 2026). The ETF's short duration mitigates rate sensitivity, but macroeconomic shifts could impact returns.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Trailing returns across standard periods
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →